Isradipine

Isradipine (PN 200-110) is an orally active L-type calcium channel blocker. Isradipine, as a powerful peripheral vasodilator, is a dihydropyridine calcium antagonist with selective actions on the heart as well as the peripheral circulation. Isradipine is a potentially viable neuroprotective agent for Parkinson's disease[1][2][3].

Product Specifications

CAS Number

[75695-93-1]

Product Name Alternative

PN 200-110

UNSPSC

12352005

Hazard Statement

H317, H319

Target

Autophagy; Calcium Channel

Type

Reference compound

Related Pathways

Autophagy; Membrane Transporter/Ion Channel; Neuronal Signaling

Applications

COVID-19-immunoregulation

Field of Research

Neurological Disease; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/isradipine.html

Purity

99.97

Solubility

DMSO : ≥ 100 mg/mL

Smiles

O=C(C1=C(C)NC(C)=C(C(OC(C)C)=O)C1C2=CC=CC3=NON=C23)OC

Molecular Formula

C19H21N3O5

Molecular Weight

371.39

Precautions

H317, H319

References & Citations

[1]Ilijic E, et al. The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson's disease. Neurobiol Dis. 2011;43 (2) :364-371.|[2]Campbell CA, et al. Effects of isradipine, an L-type calcium channel blocker on permanent and transient focal cerebral ischemia in spontaneously hypertensive rats. Exp Neurol. 1997;148 (1) :45-50.|[3]Hof RP, et al. Selective effects of PN 200-110 (isradipine) on the peripheral circulation and the heart. Am J Cardiol. 1987;59 (3) :30B-36B.